Sativex is a licenced pharmaceutical drug developed by GW Pharmaceuticals (now Jazz Pharmaceuticals) for the treatment of muscle spasticity associated with multiple sclerosis (MS). It contains a combination of two main cannabinoids extracted from the cannabis plant: delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), along with other minor cannabinoids and terpenoids.